FDA Approves First mRNA Flu Vaccine Amid Federal Skepticism and Coverage Uncertainty

The U.S. Food and Drug Administration (FDA) has approved mFlusiva, the first mRNA-based vaccine for seasonal influenza, according to reporting from Live Science. The vaccine, developed by Moderna, is approved for adults ages 50 and older, marking a shift in flu vaccine technology from traditional chicken-egg based production to messenger RNA.

While the approval is a regulatory milestone, experts told Live Science it does not necessarily signal a change in the federal government’s broader skepticism toward mRNA technology. The U.S. Department of Health and Human Services (HHS) previously terminated half a billion dollars in funding for 22 mRNA vaccine projects, and Health Secretary Robert F. Kennedy Jr. has claimed mRNA vaccines are ineffective against upper-respiratory viral infections, Live Science reported.

FDA Approval Process for mFlusiva

The path to approval for mFlusiva was described as tortured by Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, in an interview with Live Science. Moderna filed for approval in February, but the FDA initially denied the request for a materials review.

STAT News reported that career FDA scientists intended to conduct the review, but were overruled by Dr. Vinay Prasad, who was then the director of the FDA’s Center for Biologics Evaluation and Research (CBER). Dr. Offit told Live Science that the FDA had confirmed in writing in April 2024 that Moderna’s trial design was acceptable, yet Prasad denied the approval request once the data was submitted.

The denial was reversed within 15 days, and Prasad left the FDA in April, according to Jeff Coller, a distinguished professor of RNA biology and therapeutics at Johns Hopkins University, and Dr. Offit. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) subsequently voted unanimously to recommend the vaccine for adults 50 and up, leading to the official approval.

Clinical Advantages and Trial Data

mRNA-based flu vaccines offer several technical advantages over conventional shots, according to Dr. Offit. They can be produced in roughly half the time of traditional vaccines and can be more precisely tailored to match specific flu strains. In the 2025-2026 flu season, the U.S. saw at least 24,000 deaths and 390,000 hospitalizations from influenza, Live Science reported.

Trial data suggests mFlusiva provides more protection than existing options, particularly for adults aged 50 to 64. For adults over 64, who account for roughly 90% of annual flu deaths according to TechTimes, the FDA used an accelerated approval pathway. This means head-to-head clinical evidence against the current standard of care for seniors is not yet complete, and more data will be collected during the coming season to compare mFlusiva against existing high-dose flu shots.

CDC Recommendations and Insurance Coverage Gaps

FDA approval does not automatically guarantee that mFlusiva will be widely available or covered by insurance. TechTimes reports that three gaps persist: clinical guidance, insurance coverage, and the current legal status of the CDC’s advisory body.

The Advisory Committee on Immunization Practices (ACIP), which provides the clinical recommendations the CDC uses to guide vaccine deployment, is currently frozen by a federal lawsuit. A Massachusetts district court ruled on March 16, 2026, that the reconstitution of the committee by Robert F. Kennedy Jr. likely violated the Federal Advisory Committee Act, nullifying all votes taken by the reconstituted committee since June 2025, according to TechTimes.

This legal limbo affects patient costs. Under the Affordable Care Act, private insurers must cover vaccines at no cost only if they are ACIP-recommended. Because mFlusiva lacks a valid ACIP recommendation due to the court ruling, no ACA coverage mandate currently applies to the shot, TechTimes reported.

Industry Implications for mRNA Technology

Despite the political friction at HHS, the approval of mFlusiva suggests that the FDA’s statutory machinery remains functional. Jeff Coller told Live Science that the approval signals to investors and companies that the U.S. regulatory process can still operate independently of political sentiment.

I believe the more significant point is that this approval demonstrates the statutory machinery still functions when it is permitted to do so. This is of greater importance to investors and firms contemplating continued development within this U.S. sector than any particular HHS announcement.
Jeff Coller, Johns Hopkins University, via Live Science

Coller noted that a true shift in government stance would require the restoration of the 22 canceled mRNA contracts or a retraction of claims regarding the technology’s failure against respiratory viruses, neither of which has occurred.